share_log

Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target

Moomoo 24/7 ·  Apr 11 07:23

Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $35 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment